Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

NCT04970043 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer Stage II

Interventions

DRUG: Camrelizumab+ pemetrexed + platinum

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences